Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

HNMPA-(AM)3

Insulin receptor inhibitor
 
BML-EI248-0005 5 mg 118.00 USD
 
BML-EI248-0025 25 mg 465.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: ALX-430-035

HNMPA-(AM)3 is a cell-permeable analog of HNMPA. It inhibits insulin receptor tyrosine kinase activity (IC50=100 µM) and insulin-stimulated glucose oxidation in isolated rat adipocytes (IC50=10 µM). It has no effect on PKA (at concs. up to 1 mM) or PKC (at concs. up to 420 µM). Inhibits both serine and tyrosine autophosphorylation by the human insulin receptor. Does not affect protein kinase C (PKC) or cAMP-dependent protein kinase (PKA).

Product Specification

Alternative Name:Hydroxy-2-naphthalenylmethylphosphonic acid tri-acetoxymethyl ester
 
Formula:C20H23O10P
 
MW:454.4
 
CAS:120944-03-8
 
Purity:≥98% (TLC)
 
Identity:Determined by NMR.
 
Appearance:Colorless oil.
 
Solubility:Soluble in DMSO (>20mg/ml) or 100% ethanol (>20mg/ml).
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
Use/Stability:Solutions are stable for up to 3 months whn stored at -20°C. Avoid alkaline medium, pH>8.0
 
bml-ei248
Please mouse over
bml-ei248

Product Literature References

Catalysis of serine and tyrosine autophosphorylation by the human insulin receptor: K. Bantensperger et al.; PNAS 89, 7885 (1992), Abstract;
Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells: R. Saperstein et al.; Biochemistry 28, 5694 (1989), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
Insulin receptor
By biological activity:
Insulin receptor Inhibitor
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Catalogs
Diabetes Catalog
Diabetes Catalog
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,